C. Adamson

发表

HIV-1 Maturation Inhibitor Bevirimat Stabilizes the Immature Gag Lattice

A. Steven, E. Freed, J. Heymann, 2010, Journal of Virology.

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

David E. Martin, E. Freed, K. Salzwedel, 2006, Virology.

Derivatisable Cyanobactin Analogues: A Semisynthetic Approach

J. Naismith, N. Westwood, M. Migaud, 2015, Chembiochem : a European journal of chemical biology.

Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396

Terry K. Smith, N. Westwood, C. Adamson, 2016, Journal of Virology.

Impact of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors on Evolution of Resistance to the Maturation Inhibitor Bevirimat (PA-457)

E. Freed, Kayoko Waki, K. Salzwedel, 2009, Journal of Virology.

Researchin Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

E. Freed, K. Salzwedel, C. Adamson, 2010 .

Identification of Novel Inhibitors of the Type I Interferon Induction Pathway Using Cell-Based High-Throughput Screening

David W. Gray, R. Randall, D. Gray, 2016, Journal of biomolecular screening.

Far-UVC efficiently inactivates an airborne pathogen in a room-sized chamber

D. Brenner, C. Noakes, C. Adamson, 2021 .

Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets.

E. Freed, C. Adamson, 2009, Molecular interventions.

Inhibitors of the Interferon Response Enhance Virus Replication In Vitro

R. Randall, C. Adamson, Claire E. Stewart, 2014, PloS one.

Structure, regulation and function of avian glypican.

C. Adamson, E. Morkin, J. Bahl, 1998, Journal of molecular and cellular cardiology.

Novel approaches to inhibiting HIV-1 replication.

E. Freed, C. Adamson, 2010, Antiviral research.

Recent progress in antiretrovirals--lessons from resistance.

E. Freed, C. Adamson, 2008, Drug discovery today.

Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice

J. Éléouët, R. Randall, M. Rameix-Welti, 2018, Antiviral research.

Cloning and characterization of P110, a novel small nucleolar U3 ribonucleoprotein, expressed in early development.

C. Adamson, E. Morkin, J. Bahl, 2001, Experimental cell research.

Bright and Early: Inhibiting Human Cytomegalovirus by Targeting Major Immediate-Early Gene Expression or Protein Function

C. Adamson, M. Nevels, 2020, Viruses.

A block in virus-like particle maturation following assembly of murine leukaemia virus in insect cells.

I. Jones, C. Adamson, K. Mitrophanous, 2003, Virology.

The molecular basis of HIV capsid assembly—five years of progress

I. Jones, C. Adamson, Catherine S Adamson, 2004, Reviews in medical virology.

Human immunodeficiency virus type 1 assembly, release, and maturation.

E. Freed, C. Adamson, Catherine S Adamson, 2007, Advances in pharmacology.

Molecular Characterization of Feline Immunodeficiency Virus Budding

K. Nagashima, E. Freed, A. Stephen, 2007, Journal of Virology.

Control of human immunodeficiency virus type-1 protease activity in insect cells expressing Gag-Pol rescues assembly of immature but not mature virus-like particles.

I. Jones, C. Adamson, M. Nermut, 2003, Virology.

Green fluorescent protein as a reporter of prion protein folding

I. Jones, Yongxiu Yao, J. Ren, 2006, Virology Journal.

Far-UVC (222 nm) efficiently inactivates an airborne pathogen in a room-sized chamber

D. Brenner, C. Noakes, C. Adamson, 2022, Scientific Reports.

Virus maturation as a new HIV-1 therapeutic target

E. Freed, K. Salzwedel, C. Adamson, 2009, Expert opinion on therapeutic targets.

Cloning and characterization of hIF2, a human homologue of bacterial translation initiation factor 2, and its interaction with HIV-1 matrix.

A. Kingsman, S. Kingsman, C. Adamson, 1999, The Biochemical journal.

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1maturation inhibitor bevirimat

E. Freed, K. Salzwedel, C. Adamson, 2010, Retrovirology.

Protease-MediatedMaturation of HIV : Inhibitors of Protease and theMaturation Process

C. Adamson, 2014 .

Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process

C. Adamson, 2012, Molecular biology international.

Impact of Human Immunodeﬁciency Virus Type 1 Resistance to Protease Inhibitors on Evolution of Resistance to the Maturation Inhibitor Bevirimat (PA-457) (cid:1) †

E. Freed, Kayoko Waki, K. Salzwedel, 2009 .

Two mouse mutations mapped to chromosome 11 with differing morphologies but similar progressive inflammatory alopecia.

A. Flenniken, C. McKerlie, K. Fleming, 2005 .

Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector

M. F. White, C. Adamson, S. Grüschow, 2021, bioRxiv.

Antiviral drug discovery: preparing for the next pandemic.

K. Chibale, R. Dorrington, D. Newman, 2021, Chemical Society reviews.

In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat)

Kunio Nagashima, K. Nagashima, E. Freed, 2006, Journal of Virology.

Novel single chain antibodies to the prion protein identified by phage display.

M. Sy, I. Jones, Yongxiu Yao, 2007, Virology.

Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection.

J. Moore, A. Hurley, M. Markowitz, 2000, AIDS research and human retroviruses.

Stabilizes the Immature Gag Lattice HIV-1 Maturation Inhibitor Bevirimat

A. Steven, E. Freed, J. Heymann, 2012 .

Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.

E. Freed, A. Stephen, R. Fisher, 2006, Organic letters.